{"componentChunkName":"component---src-templates-chapter-level-2-chapter-level-2-tsx","path":"/topics/trigeminal-neuralgia/prescribing-information/carbamazepine/","result":{"pageContext":{"chapter":{"id":"74b691ce-0764-54e6-a932-11f0755c3089","slug":"carbamazepine","fullItemName":"Carbamazepine","depth":2,"htmlHeader":"<!-- begin field 8d1121a1-d7d4-4d97-a07d-7c5ed7426679 --><h2>Carbamazepine</h2><!-- end field 8d1121a1-d7d4-4d97-a07d-7c5ed7426679 -->","summary":"","htmlStringContent":"<!-- begin item 70690527-15ed-419c-8079-3d84779f387d --><!-- end item 70690527-15ed-419c-8079-3d84779f387d -->","topic":{"id":"b411a210-e8ef-56d4-8840-714bb3ca8b7d","topicId":"dd0f36c2-b31b-42ca-bc80-17ddb7e243ec","topicName":"Trigeminal neuralgia","slug":"trigeminal-neuralgia","lastRevised":"Last revised in January 2018","chapters":[{"id":"5a46b0ae-84bb-5e91-9f06-d82e7de90660","fullItemName":"Summary","slug":"summary","subChapters":[]},{"id":"6ebb1131-0f9c-5613-9b6d-c44044dc3d59","fullItemName":"Have I got the right topic?","slug":"have-i-got-the-right-topic","subChapters":[]},{"id":"04895c32-0679-538d-bd7f-566f3b1aca33","fullItemName":"How up-to-date is this topic?","slug":"how-up-to-date-is-this-topic","subChapters":[{"id":"064b944d-9f86-5ad2-bdde-418e427a69cf","slug":"changes","fullItemName":"Changes"},{"id":"215b2ed2-a6ff-5053-b74a-72ca907fbb6f","slug":"update","fullItemName":"Update"}]},{"id":"0d57219c-f171-59f5-b932-8cabc9dd5049","fullItemName":"Goals and outcome measures","slug":"goals-outcome-measures","subChapters":[{"id":"d78c8e6b-affd-55c5-8e55-1db5bbe57261","slug":"goals","fullItemName":"Goals"},{"id":"135b5ce1-adf5-5fa9-8d6a-a90e64183628","slug":"outcome-measures","fullItemName":"Outcome measures"},{"id":"2dd53a4e-0dcf-5797-90d1-ac0ae3a56a93","slug":"audit-criteria","fullItemName":"Audit criteria"},{"id":"a8fd6b61-b1c3-538d-b032-872f1d3427c2","slug":"qof-indicators","fullItemName":"QOF indicators"},{"id":"7d867bfa-0e88-5dbe-85c4-50f28d24c9c8","slug":"qipp-options-for-local-implementation","fullItemName":"QIPP - Options for local implementation"},{"id":"38f48973-5497-53e5-a936-4b59cbd4b662","slug":"nice-quality-standards","fullItemName":"NICE quality standards"}]},{"id":"ff1b2d66-75ed-51c6-bfa9-fcc0ad6d6bac","fullItemName":"Background information","slug":"background-information","subChapters":[{"id":"2e9fdd75-4a7e-56ad-8c9d-02ac90da26bd","slug":"definition","fullItemName":"Definition"},{"id":"4dc2aba7-3510-51d4-9aab-2596d348bd1a","slug":"causes","fullItemName":"Causes"},{"id":"6e2bbd60-dabb-5cdb-86d0-29bd0a23615b","slug":"risk-factors","fullItemName":"Risk factors"},{"id":"7c45985c-eb6e-5f96-9d9b-44cc50b51476","slug":"prevalence","fullItemName":"Prevalence"},{"id":"16848fcb-77c6-5043-9c84-eadffb6ff3aa","slug":"prognosis","fullItemName":"Prognosis"},{"id":"a7f1ea99-b3b5-5e53-952d-515327e12d83","slug":"complications","fullItemName":"Complications"}]},{"id":"5c22d7af-254a-51f1-a8b9-07efa299f48b","fullItemName":"Diagnosis","slug":"diagnosis","subChapters":[{"id":"bbf28df3-9b64-5c32-85b5-26dc3c2cc0af","slug":"diagnosis","fullItemName":"Diagnosis"}]},{"id":"feea47e1-4766-5814-8cd9-3adf7df4600f","fullItemName":"Management","slug":"management","subChapters":[{"id":"5008bdc5-02f7-558d-9c72-fa0bd4f2c01a","slug":"management","fullItemName":"Scenario: Management"}]},{"id":"ff7b11db-4087-5134-804a-f231a32cf2ce","fullItemName":"Prescribing information","slug":"prescribing-information","subChapters":[{"id":"74b691ce-0764-54e6-a932-11f0755c3089","slug":"carbamazepine","fullItemName":"Carbamazepine"}]},{"id":"ae57d488-a470-558c-b5d7-81fb47f8fbad","fullItemName":"Supporting evidence","slug":"supporting-evidence","subChapters":[]},{"id":"90e907d0-34e8-53cc-a9f6-53b0de5c633c","fullItemName":"How this topic was developed","slug":"how-this-topic-was-developed","subChapters":[{"id":"c39bcb69-119d-5f65-927c-00c82813d6f3","slug":"search-strategy","fullItemName":"Search strategy"},{"id":"614a98b5-320e-5735-b0f4-c72808b83068","slug":"stakeholder-engagement","fullItemName":"Stakeholder engagement"},{"id":"4c55bb70-6e39-5673-898f-4244d6e219e7","slug":"evidence-exclusion-criteria","fullItemName":"Evidence exclusion criteria"},{"id":"5b8a3490-a3c6-565b-9f06-fc347a6c2eb4","slug":"organizational-behavioural-financial-barriers","fullItemName":"Organizational, behavioural and financial barriers"},{"id":"12e3df2a-fa39-57fa-b4ef-e222cd41fa5b","slug":"declarations-of-interest","fullItemName":"Declarations of interest"}]},{"id":"d1abb506-cecf-562c-84a9-1e2167e7129f","fullItemName":"References","slug":"references","subChapters":[]}]},"parentChapter":{"id":"ff7b11db-4087-5134-804a-f231a32cf2ce","slug":"prescribing-information","fullItemName":"Prescribing information"},"subChapters":[{"id":"ea3df436-8e36-5fc7-b0f2-433d2ae4ab98","slug":"contraindications-cautions","fullItemName":"Contraindications and cautions","depth":3,"htmlHeader":"<!-- begin field 026a284f-36cb-49d8-b7a5-09fd6f3b5f2a --><h3>Contraindications and cautions</h3><!-- end field 026a284f-36cb-49d8-b7a5-09fd6f3b5f2a -->","summary":"","htmlStringContent":"<!-- begin item a58a38d0-e6c3-4d2b-9c44-24161e6bbfb3 --><!-- begin field c1f07dac-e9ec-4859-82b3-1a7f82fbf3a8 --><ul><li>Do not prescribe carbamazepine to people:<ul><li>With a known hypersensitivity to carbamazepine or structurally related drugs (for example tricyclic antidepressants) or any other component of the formulation.</li><li>With atrioventricular block.</li><li>With a history of bone marrow depression.</li><li>With a history of hepatic porphyrias.</li><li>Taking a monoamine oxidase inhibitor.</li></ul></li><li>Prescribe carbamazepine with caution to people:<ul><li>At risk of suicide.</li><li>With cardiac disease.</li><li>With a history of haematological reactions to other drugs.</li><li>With a history of absence and myoclonic seizures.</li><li>Who are susceptible to angle-closure glaucoma.</li></ul></li></ul><p>[<a class=\"bibliography-reference internal-reference\" href=\"/topics/trigeminal-neuralgia/references/\">ABPI, 2015</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/trigeminal-neuralgia/references/\">BNF 72, 2016</a>]</p><!-- end field c1f07dac-e9ec-4859-82b3-1a7f82fbf3a8 --><!-- end item a58a38d0-e6c3-4d2b-9c44-24161e6bbfb3 -->","subChapters":[]},{"id":"9456f515-652a-5967-ba15-2c3e33b7f4c8","slug":"adverse-effects","fullItemName":"Adverse effects","depth":3,"htmlHeader":"<!-- begin field d1e4fb2b-9b2d-46d9-aea8-1d479791c5d2 --><h3>What are the adverse effects and how can they be managed?</h3><!-- end field d1e4fb2b-9b2d-46d9-aea8-1d479791c5d2 -->","summary":"","htmlStringContent":"<!-- begin item 9bb8a8fd-311b-4e45-944d-acd6ea56b689 --><!-- begin field ebbbbaaa-a22e-4deb-88f0-eb469c61d4d0 --><ul><li>Common adverse effects of carbemazepine include nausea and vomiting, sedation, dizziness, and ataxia.<ul><li>These adverse effects are dose related and are most common at the start of treatment and in older people.</li><li>Switching to a modified-release preparation of carbamazepine may help to reduce the incidence of central nervous system adverse effects, such as sedation.</li></ul></li><li>Allergic skin reactions (including urticaria, which may be severe) are also common:<ul><li>Withdraw carbamazepine if the skin reaction worsens, or is accompanied by other symptoms.</li></ul></li><li>Rarely, serious dermatological adverse effects, including Stevens-Johnson syndrome and exfoliative dermatitis, can occur.<ul><li>People who are of Han Chinese, Hong Kong Chinese, or Thai origin should be screened for the presence of the HLA–B*1502 allele before taking carbamazepine. Those who test positive should not start carbamazepine unless there is no other treatment option.</li><li>Testing for this allele should also be considered in people originating from Malaysia and the Philippines.</li></ul></li><li>Hyponatraemia occurs in 20% of people taking carbamazepine. It is usually mild but in rare cases can lead to water intoxication accompanied by lethargy, vomiting, headache, and confusion.<ul><li>Consider hyponatraemia if the person develops dizziness, drowsiness, confusion, nausea, muscle cramps, or seizures.</li><li>If hyponatraemia is suspected, reduce the dose or stop carbamazepine and manage according to severity of symptoms, duration, and state of hydration.</li></ul></li><li>Leucopenia (very common) and other blood disorders (including thrombocytopenia, agranulocytosis, and aplastic anaemia) may occur with carbamazepine treatment.</li><li>Advise people taking carbamazepine to seek immediate medical attention if they develop symptoms indicative of blood, hepatic, or skin disorders (for example fever, sore throat, rash, mouth ulcers, bruising, or bleeding).</li><li>There is a small risk of suicidal thoughts and behaviour associated with antiepileptic drugs, which may be seen as early as one week after starting treatment.<ul><li>People taking carbamazepine and healthcare professionals should be alert to any mood changes, distressing thoughts, or feelings about suicide or self-harm at any point during treatment.</li></ul></li></ul><p>[<a class=\"bibliography-reference internal-reference\" href=\"/topics/trigeminal-neuralgia/references/\">ABPI, 2015</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/trigeminal-neuralgia/references/\">BNF 72, 2016</a>]</p><!-- end field ebbbbaaa-a22e-4deb-88f0-eb469c61d4d0 --><!-- end item 9bb8a8fd-311b-4e45-944d-acd6ea56b689 -->","subChapters":[]},{"id":"e3bff568-7eb4-50cd-87f8-2c75b31eed73","slug":"drug-interactions","fullItemName":"Drug interactions","depth":3,"htmlHeader":"<!-- begin field 0e10482d-6971-4081-a452-618e34117ce8 --><h3>Drug interactions</h3><!-- end field 0e10482d-6971-4081-a452-618e34117ce8 -->","summary":"","htmlStringContent":"<!-- begin item 979b089d-82cf-43d7-9967-3c00ef44d9fe --><!-- begin field 8e86c47c-20ab-44e6-b81e-d033acbaa847 --><ul><li>The use of carbamazepine is not recommended in combination with monoamine oxidase inhibitors (MAOIs), or for 2 weeks after stopping an MAOI.</li><li>Avoid giving carbamazepine with diuretics — increased risk of hyponatraemia.</li><li>The plasma concentration of carbamazepine may be increased (with an increased risk of toxicity) by the concomitant use of certain drugs, including:<ul><li>Acetazolamide.</li><li>Antidepressants— fluoxetine, fluvoxamine, paroxetine, trazodone.</li><li>Azole antifungals.</li><li>Antivirals — protease inhibitors for HIV treatment (for example ritonavir).</li><li>Cimetidine.</li><li>Ciprofloxacin.</li><li>Danazol.</li><li>Dextropropoxyphene.</li><li>Diltiazem.</li><li>Isoniazid.</li><li>Olanzapine.</li><li>Omeprazole</li><li>Verapamil.</li><li>Vigabatrin.</li></ul></li><li>Carbamazepine accelerates the metabolism of certain drugs, including:<ul><li>Ciclosporin — resulting in reduced levels of ciclosporin.</li><li>Clozapine — resulting in reduced plasma concentration of clozapine; also avoid concomitant use of drugs with potential for causing agranulocytosis.</li><li>Corticosteroids (systemic) — resulting in their reduced effect.</li><li>Direct acting oral anti-coagulants (DOACs: rivaroxaban, dabigatran, apixaban and edoxaban) may lead to reduced plasma concentrations of DOACs, which carries the risk of thrombosis. Closer monitoring is recommended</li><li>Doxycycline — resulting in reduced effect.</li><li>Oestrogens and progestogens — resulting in reduced effect of oral contraceptives.</li><li>Thyroid hormones — requirements for thyroid hormones in hypothyroidism may be increased.</li><li>Tricyclic antidepressants — resulting in their reduced effect.</li><li>Simvastatin — consider increasing dose of simvastatin; statins metabolized by the same route as simvastatin may also have their levels reduced.</li><li>Warfarin — resulting in reduced anticoagulant effect.</li></ul></li><li>Other interactions include:<ul><li>Lithuim — may result in enhanced neurotoxicity despite lithium plasma concentrations being within the therapeutic range.</li><li>Paracetamol — long term co-administration may result in hepatotoxicity. </li><li>Primidone, progabide, quetiapine, valproic acid, valnoctamide and valpromide — may result in raised plasma levels of the active metabolite carbamazepine-10,11-epoxide, increasing the risk of adverse reactions (e.g. dizziness, drowsiness, ataxia, diplopia). The dosage of carbemazepine should be adjusted accordingly and/or the plasma levels monitored when used concomitantly with these substances.</li></ul></li></ul><p>[<a class=\"bibliography-reference internal-reference\" href=\"/topics/trigeminal-neuralgia/references/\">Baxter and Preston, 2013</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/trigeminal-neuralgia/references/\">ABPI, 2015</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/trigeminal-neuralgia/references/\">BNF 72, 2016</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/trigeminal-neuralgia/references/\">ABPI, 2018</a>] </p><!-- end field 8e86c47c-20ab-44e6-b81e-d033acbaa847 --><!-- end item 979b089d-82cf-43d7-9967-3c00ef44d9fe -->","subChapters":[]},{"id":"cf18967b-0be2-5a80-9a5c-3ca5143de6fb","slug":"monitoring","fullItemName":"Monitoring","depth":3,"htmlHeader":"<!-- begin field 7de2c0ce-85bf-4392-bd4b-7acb64db6ec5 --><h3>What monitoring is required?</h3><!-- end field 7de2c0ce-85bf-4392-bd4b-7acb64db6ec5 -->","summary":"","htmlStringContent":"<!-- begin item 08bf86ce-9e6d-49e8-a86d-6bd3223c7351 --><!-- begin field 3fe0e3d4-aed1-4b9a-bddd-f64ed77924d3 --><ul><li>Serum carbamazepine levels should not be routinely monitored unless toxicity is suspected.</li><li>A full blood count should ideally be done before starting treatment, and periodically thereafter.<ul><li>If the white blood cell or platelet count is low or decreased during treatment, the person should be closely monitored.</li><li>Stop treatment if leucopenia develops that is severe, progressive, or accompanied by clinical symptoms (e.g. fever or sore throat), or if there is any evidence of significant bone marrow depression.</li></ul></li><li>Liver function tests should also be performed before commencing treatment and periodically thereafter, particularly in patients with a history of liver disease and in elderly patients.<ul><li>The drug should be withdrawn immediately in cases of aggravated liver dysfunction or acute liver disease.</li><li>Some liver function tests in patients receiving carbamazepine may be found to be abnormal, particularly gamma glutamyl transferase. This is probably due to hepatic enzyme induction. Enzyme induction may also produce modest elevations in alkaline phosphatase. </li></ul></li></ul><p>[<a class=\"bibliography-reference internal-reference\" href=\"/topics/trigeminal-neuralgia/references/\">ABPI, 2015</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/trigeminal-neuralgia/references/\">BNF 72, 2016</a>]</p><!-- end field 3fe0e3d4-aed1-4b9a-bddd-f64ed77924d3 --><!-- end item 08bf86ce-9e6d-49e8-a86d-6bd3223c7351 -->","subChapters":[]}]}}},"staticQueryHashes":["3666801979"]}